Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025)
Century Therapeutics (IPSC) reported EBITDA Margin of 70.12% for Q1 2025, up 339304.0% year-over-year from N/an in Q1 2024, and up 108.01% quarter-over-quarter from 874.84% in Q4 2024.
Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025) Analysis & Trends
Century Therapeutics (IPSC) has 4 years of EBITDA Margin data on file, last reported at 70.12% in Q1 2025.
- EBITDA Margin for Q1 2025 came in at 70.12%, up 339304.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 9.04% (up 190829.0% YoY), and the FY2025 annual result was 9.05%, up 190854.0% from the prior year.
- EBITDA Margin rose to 70.12% in Q1 2025 per IPSC's latest filing, from 874.84% in the prior quarter.
- Over five years, EBITDA Margin peaked at 70.12% in Q1 2025 and troughed at 33558.59% in Q2 2023.
- A 4-year average of 7454.87% and a median of 3733.93% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 3128208 bps in 2023, then jumped 2950217 bps in 2024.
- A 4-year view of EBITDA Margin shows it stood at 5861.8% in 2022, then slumped by 142 bps to 14173.13% in 2023, then surged by 94 bps to 874.84% in 2024, then soared by 108 bps to 70.12% in 2025.
- Business Quant data shows IPSC's EBITDA Margin at 70.12% in Q1 2025, 874.84% in Q4 2024, and 3812.77% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Century Therapeutics | 444.99 Mn | 444.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 70.12% |
| Dec 31, 2024 | -874.84% |
| Sep 30, 2024 | -3,812.77% |
| Jun 30, 2024 | -4,056.42% |
| Mar 31, 2024 | -3,322.92% |
| Dec 31, 2023 | -14,173.13% |
| Sep 30, 2023 | -22,173.65% |
| Jun 30, 2023 | -33,558.59% |
| Mar 31, 2023 | -1,748.66% |
| Dec 31, 2022 | -5,861.80% |
| Sep 30, 2022 | -1,390.24% |
| Jun 30, 2022 | -2,276.50% |
| Mar 31, 2022 | -3,733.93% |